Navigation Links
AEterna Zentaris Receives US$5.5 Million from Institutional Investors
Date:10/24/2009

QUEBEC CITY, Oct. 23 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), (the "Company") a global biopharmaceutical company focused on endocrine therapy and oncology, announced today that it has completed its previously announced registered direct offering of US$5.5 million of units comprised of common shares and common share purchase warrants to certain institutional investors. AEterna Zentaris received net proceeds of approximately US$5.1 million after deducting placement agent fees and other offering expenses. All of the common shares and warrants were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used for general corporate purposes, including clinical development of the Company's leading compounds.

Juergen Engel, Ph. D., President and CEO of AEterna Zentaris stated, "We are very pleased with this vote of confidence from targeted specialized institutional investors. In addition, completing this financing provides us with additional funds that will help us to continue to further strengthen and advance our promising pipeline."

As of October 23, 2009 and after issuing 4,583,335 common shares at the closing of the offering, the Company had 63,089,954 common shares issued and outstanding without giving effect to or assuming the exercise of any outstanding warrants.

A shelf registration statement relating to the common shares and warrants issued in the offering (and the common shares issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective. A prospectus supplement relating to the offering was filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from AEterna Zentaris Inc., 1405 du Parc-Technologique Boulevard, Quebec City, Canada G1P 4P5. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of AEterna Zentaris' common shares or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq: RODM), acted as the exclusive placement agent for the transaction.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.

SOURCE AETERNA ZENTARIS INC.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  BioGenex, a ... announce development of a novel system for quantitative ... with the University of Rochester (NY, USA) and ... The new system is able to accurately quantify ... HER2 (Human epidermal growth factor receptor-2) in clinical ...
(Date:2/16/2017)... ... February 16, 2017 , ... Avomeen & MichBio will be hosting a ... held at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan 48108). BioMixers ... an opportunity to interact with peers, make new connections and talk bio biz. , ...
(Date:2/16/2017)... -- Research and Markets has announced the ... report to their offering. ... The study scope ... plasmids, chassis organisms, synthetic cells, production systems), enabling technologies ... and specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, ...
(Date:2/16/2017)... , Feb. 16, 2017  Dermata Therapeutics, ... products to treat a variety of dermatological diseases, ... Series 1a financing and entered into a $5 ...  Dermata intends to use the capital for general ... major advancements in the treatment of serious diseases ...
Breaking Biology Technology:
(Date:1/24/2017)... , Jan. 24, 2017  It sounds simple ... sock that monitors vital signs and alerts parents ... infant,s oxygen saturation level drops. But pediatric experts ... to parents, with no evidence of medical benefits, ... are marketed aggressively to parents of healthy babies, ...
(Date:1/19/2017)... , Jan. 19, 2017 Sensory ... experience and security for consumer electronics, and ... processing systems and cybersecurity solutions, today announced a ... and financial institutions worldwide to bolster security of ... end-to-end secure user authentication platforms they offer, innerCore ...
(Date:1/12/2017)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer ... it has signed agreements with seven strategic partners across ... Middle East for commercialization of the Trovera™ ... of international distribution agreements for Trovagene,s CLIA based liquid ... The initial partners will introduce Trovagene,s liquid biopsy tests ...
Breaking Biology News(10 mins):